What are the Historical Developments and Current Growth Metrics of the Gouty Arthritis Market?
The gouty arthritis market has seen considerable growth due to a variety of factors.
• The gouty arthritis market has expanded significantly in recent years. It will grow from $3.44 billion in 2024 to $3.7 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.6%.
This growth is linked to the high prevalence of chronic diseases, rising alcohol consumption, an increasing elderly population, growing acceptance of enhanced regeneration therapies, and higher healthcare expenditures.
What is the Forecasted Market Size and CAGR for the Gouty Arthritis Market?
The gouty arthritis market is expected to maintain its strong growth trajectory in upcoming years.
• The gouty arthritis market is expected to grow strongly, reaching $4.9 billion by 2029, at a CAGR of 7.2%.
The growth will be driven by improvements in healthcare infrastructure, rising obesity rates, the increasing incidence of gout, and growing public awareness. Key trends will include rising demand for effective treatments, regenerative therapies, technological advancements, new product launches, and regulatory approvals.
What Key Factors and Trends Are Driving The Growth Gouty Arthritis Market?
The increasing prevalence of obesity is expected to drive the growth of the gouty arthritis market. Obesity leads to higher uric acid production, which can result in gout, a form of arthritis. According to the World Health Organization, about 1 billion individuals were classified as obese in 2022, and this figure continues to rise. The increase in obesity rates contributes to the growth of the gouty arthritis market.
What Are The Market Segments In The Gouty Arthritis Market?
The gouty arthritis market covered in this report is segmented –
1) By Type: Acute Gouty Arthritis, Chronic Gouty Arthritis
2) By Treatment: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Pain Reliever, Corticosteroids, Xanthine Oxidase Inhibitors, Uricosurics, Others Treatments
3) By Diagnosis: Joint Fluid Test, Blood Test, X-Ray Imaging, Ultrasound, Dual Energy Computed Tomography (CT) Scan, Other Diagnosis
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Others Distribution Channels
5) By End-Users: Hospitals, Specialty Clinics, Other End-Users
Subsegments:
1) By Acute Gouty Arthritis: Monosodium Urate Crystals-Induced Acute Gout, Acute Gout Attack (Intermittent Flares), Severe Acute Gout With Joint Deformities
2) By Chronic Gouty Arthritis: Tophaceous Gout (Presence Of Uric Acid Deposits), Chronic Gout With Joint Damage, Chronic Gout With Renal Complications, Chronic Gout With Comorbidities (Hypertension, Diabetes)
Pre-Book The Gouty Arthritis Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Shaping The Gouty Arthritis Market?
Leading firms within the gouty arthritis market are amplifying their efforts to create innovative products, such as cortrophin gel, aiming to offer more effective and targeted treatments for the ailment. Cortrophin gel, or repository corticotropin injection, is a refined version of the adrenocorticotropic hormone (ACTH). It's used to manage a variety of inflammatory and autoimmune situations, including gouty arthritis. For example, in October 2023, the Food and Drug Administration granted approval to ANI Pharmaceuticals, a pharmaceutical company based in the US, for a new 1-mL vial size of Purified Cortrophin Gel. This product is designed for the supplementary treatment of certain patients suffering from severe gouty arthritis outbreaks. At present, Cortrophin Gel is the only FDA-approved adrenocorticotropic hormone (ACTH) medication suggested for the treatment of suitable patients with acute gouty arthritis flare-ups.
Who Are the Key Players In The Gouty Arthritis Market?
Major companies operating in the gouty arthritis market are:
• Pfizer Inc.
• Roche Holding AG
• Merck & Co. Inc.
• AbbVie Inc.
• Bayer AG
• Bristol Myers Squibb
• AstraZeneca plc
• Novartis International AG
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Amgen Inc.
• Gilead Sciences Inc.
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals Inc.
• Biogen Inc.
• Vertex Pharmaceuticals Incorporated
• UCB S.A.
• Boehringer Ingelheim International GmbH
• Sun Pharmaceutical Industries Ltd.
• Horizon Therapeutics plc
• Dr. Reddy's Laboratories Ltd.
• Amneal Pharmaceuticals Inc.
• Lupin Pharmaceuticals Inc.
What Are The Regional Insights Into The Gouty Arthritis Market?
North America was the largest region in the gouty arthritis market in 2023. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the gouty arthritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
